However, although this finding regarding CXCL5 is consistent with the conclusion from a study of melanoma treated with nivolumab (90), the impact of CXCL5 on the TIME seems contradictory to its role as a positive biomarker, considering a study from skin cancers demonstrated that CXCL5 secreted by TAMs recruits MDSCs to the TME via the CXCR2-CXCL5 axis, exerting immunosuppressive effects (85). Here, CXCL5 is linked to skin cancer.